Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
11 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
0.2877
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
January 24, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
January 19, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
January 04, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
January 04, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
December 13, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
December 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Adopts Limited Duration Shareholder Rights Plan
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
November 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
November 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
November 22, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
November 15, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
November 10, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
October 31, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC)
October 16, 2023
Via
ACCESSWIRE
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
October 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
October 13, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
October 11, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted European Patent for its Core Technology
October 03, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
September 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces 1-for-26 Reverse Share Split
September 20, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
September 12, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.